I mostly agree with Lyn.
If they're going to target all the pelvic lymph nodes (some of which go around the rectum), which is probably a good idea since you're N1, I'm not sure how much benefit a rectal spacer is. That's something you could ask.
Completely agree on SBRT verses EBRT (which would be IG-VMAT in the UK). EBRT spills outside the target area in a way which is probably advantageous to you, for mopping up micro-mets (any mets too small to show on scans). Brachytherapy boost might be useful to boost the effect inside the prostate and seminal vesicles (needs to be HDR brachy to include seminal vesicles), and this would be done in addition to EBRT at a lower dose, but I'm not completely sure if that makes sense if you're N1.
Abiraterone is offered with neoadjuvant/adjuvant hormone therapy (that's hormone therapy before/after radiotherapy) in many countries now with claimed better outcomes. There was already some evidence that getting PSA lower before radiotherapy improved outcomes and Abiraterone will help with this, but that's probably not the only effect at play. We've known for some time that hitting cancer from several directions at once can help outcomes, and the Abiraterone is another direction.
On the NHS, I managed to get some of this effect (without Abiraterone) by extending my neoadjuvant hormone therapy until my PSA was down to 0.1 - that took me 5 months rather than the 3 months neoadjuvant hormone therapy they originally suggested. This doesn't extend the total time on hormone therapy (indeed, there's research suggesting you can reduce it if you get down to 0.1 before starting RT).
Since you are young and in the process of having a family, you should also look into sperm banking before you start on the hormone therapy.
Edited by member 13 Oct 2021 at 23:38
| Reason: Not specified